On a disclosed basis, revenue was KRW 48.1 billion in 2022, KRW 53.7 billion in 2023, KRW 54.9 billion in 2024 and KRW 69.6 billion in 2025, rising for three straight years from 2023 through 2025, with 2025 up 26.6%.
The operating loss was KRW 7.88 billion in 2022, KRW 8.7 billion in 2023, KRW 7.62 billion in 2024 and KRW 3.53 billion in 2025, a loss in each of the four years, and the operating margin improved from -16.4% in 2022 to -5.1% in 2025.
The attributable net loss was KRW 11.4 billion in 2022, KRW 2.3 billion in 2023, KRW 22.8 billion in 2024 and KRW 9.23 billion in 2025, while the net loss including non-controlling interests was KRW 12.1 billion, KRW 3.08 billion, KRW 23.5 billion and KRW 9.67 billion for the same years.
The debt-to-equity ratio was 46.5% in 2022, 17.1% in 2023, 20.9% in 2024 and 31.5% in 2025, and at the end of 2025 total equity was KRW 173.9 billion, of which equity attributable to owners of the parent was KRW 150.3 billion, with total liabilities of KRW 54.8 billion.
Operating cash flow was -KRW 8.81 billion in 2022, KRW 3.33 billion in 2023, KRW 1.29 billion in 2024 and -KRW 8.18 billion in 2025.
On a quarterly basis, revenue was KRW 16.1 billion in Q3 2025 with an operating loss of KRW 5.38 billion, then turned to an operating profit of KRW 4.09 billion in Q4 2025 on revenue of KRW 22.8 billion.
Revenue fell 42.7% quarter on quarter to KRW 13 billion in Q1 2026, with an operating loss of KRW 3.24 billion, and the operating loss widened to KRW 4.73 billion in Q2 2026 on revenue of KRW 12.6 billion.
Q3 2026 revenue was KRW 20.6 billion, up 63.7% quarter on quarter and 28.0% year on year, and the operating loss narrowed to KRW 4.11 billion.
However, the attributable net loss of KRW 6.37 billion in Q3 2026 was larger than the KRW 5.48 billion loss in Q3 2025, so the operating and attributable results moved in different directions.
Per the 2026 half-year report, first-half consolidated revenue of KRW 25.6 billion was down 16.6% year on year, and press coverage attributed the decline to lower public vaccine distribution volumes after a shift in COVID-19 vaccine mix.